Results 21 to 30 of about 497,020 (311)

Tumor necrosis factor-alpha in patients with alopecia areata

Indian Journal of Dermatology, 2011
Background : Alopecia areata (AA) is a common form of localized, nonscarring hair loss. It is characterized by the loss of hair in patches, total loss of scalp hair (alopecia totalis, AT), or total loss of body hair (alopecia universalis, AU).
Emina Kasumagic-Halilovic, Asja Prohic, Semra Cavaljuga   +2 more
doaj   +1 more source

Single-cell multi-omics reveals the TNF-α activation threshold for Classical Monocytes by studying healthy donors and rheumatoid arthritis patients

Frontiers in Immunology
IntroductionTumor Necrosis Factor Alpha is a known pro-inflammatory cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Anti-cytokine therapies targeting Tumor Necrosis Factor Alpha have greatly succeeded in treating rheumatoid ...
Roman Perik-Zavodskii, Roman Perik-Zavodskii, Olga Perik-Zavodskaia, Saleh Alrhmoun, Saleh Alrhmoun, Julia Lopatnikova, Julia Lopatnikova, Alina Alshevskaya, Julia Zhukova, Julia Zhukova, Julia Shevchenko, Julia Shevchenko, Nadezhda Shkaruba, Natalia Sivitskaya, Shakir Suleimanov, Elizaveta Sheveleva, Kirill Nazarov, Fedor Kireev, Fedor Kireev, Alexey Sizikov, Elena Golikova, Sergey Sennikov, Sergey Sennikov   +22 more
doaj   +1 more source

Tumor Necrosis Factor Alpha in Amyotrophic Lateral Sclerosis: Friend or Foe?

Cells, 2021
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a massive neuroinflammatory reaction, which plays a key role in the progression of the disease.
Giulia Guidotti, Chiara Scarlata, Liliana Brambilla, Daniela Rossi   +3 more
doaj   +1 more source

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

Journal of Experimental Medicine, 1991
Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the
E. Sampaio, E. Sarno, R. Galilly, Z. Cohn, G. Kaplan   +4 more
semanticscholar   +1 more source

Glaucomatous neurodegeneration: An eye on tumor necrosis factor-alpha

Indian Journal of Ophthalmology, 2012
Glaucoma, a neurodegenerative disease, is currently being treated by modulation of one of its primary risk factors, the elevated intraocular pressure. Newer therapies that can provide direct neuroprotection to retinal ganglion cells are being extensively
Renu Agarwal, Puneet Agarwal
doaj   +1 more source

From omics to AI—mapping the pathogenic pathways in type 2 diabetes

FEBS Letters, EarlyView.
Integrating multi‐omics data with AI‐based modelling (unsupervised and supervised machine learning) identify optimal patient clusters, informing AI‐driven accurate risk stratification. Digital twins simulate individual trajectories in real time, guiding precision medicine by matching patients to targeted therapies.
Siobhán O'Sullivan, Lu Qi, Pierre Zalloua   +2 more
wiley   +1 more source

Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report [PDF]

Anais Brasileiros de Dermatologia, 2014
The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among ...
Clarissa Luiza Dalla Bernardina Carvalho, Luciena Cegatto Martins Ortigosa   +1 more
doaj   +1 more source

Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells

FEBS Letters, EarlyView.
Imeglimin, at clinically relevant concentrations, inhibits vesicular ATP accumulation and release from hepatic stellate cells, thereby attenuating purinergic signaling and reducing fibrogenic activation. This mechanism reveals a newly identified antifibrotic action of imeglimin beyond glycemic control.
Seiji Nomura, Lixiang Wang, Nao Hasuzawa, Ayako Nagayama, Sawako Moriyama, Kenji Ashida, Yoshinori Moriyama, Masatoshi Nomura, Ken Yamamoto   +8 more
wiley   +1 more source

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

Tumor Necrosis Factor-Alpha and Mast Cells: Revisited Study

European Journal of Inflammation, 2011
Mast cells reside in connective tissues and are widely recognized as effector cells important in innate and acquired immunity. These cells are the only ones capable of storing preformed TNFα in their cytoplasmatic granules and release upon activation ...
A. Saggini, D. Tripodi, G. Maccauro, M.L. Castellani, A. Anogeianaki, S. Teté, P. Felaco, M.A. De Luths, R. Galzio, M. Fulcheri, T.C. Theoharides, A. Caraffa, P. Antinolfi, M. Felaco, F. Conti, G. Neri, F. Pandolfi, E. Tomato, Y.B. Shaik-Dasthagirisaheb   +18 more
doaj   +1 more source